Cellulite Treatment Market

Market Definition

The market focuses on developing solutions to reduce or eliminating cellulite, a common condition causing skin irregularities, primarily on the thighs, buttocks, and abdomen. It includes non-invasive procedures (laser therapy, radiofrequency, ultrasound), minimally invasive treatments (subcision, injectable fillers), and topical products (creams, lotions, and serums). 

This report delves into the critical drivers fueling market development, offering a detailed regional analysis and an overview of the competitive landscape shaping future opportunities.

Cellulite Treatment Market Overview

The global cellulite treatment market size was valued at USD 1780.0 million in 2023 and is projected to grow from USD 1980.4million in 2024 to USD 4527.3 million by 2031, exhibiting a CAGR of 12.54% during the forecast period.

Increasing consumer awareness regarding aesthetic treatments, advancements in non-invasive and minimally invasive cellulite reduction technologies, and the rising demand for body contouring procedures are fueling market growth. These factors, combined with a growing emphasis on self-care and enhanced beauty standards, are driving the adoption of cellulite treatments across diverse consumer segments.

Major companies operating in the cellulite treatment industry are Alma Lasers Ltd, AbbVie Inc, Merz Pharma, REVANCE AESTHETICS., Zimmer MedizinSystems Aesthetic Division, Galderma, Hologic, Inc., Cutera Aesthetics, Lumenis Be Ltd, Beijing Nubway S&T Co.,Ltd., Inceler Medikal Co. Ltd., Candela Corporation, Bausch Health Companies Inc, Inmode Ltd, and ENDYMED.

The adoption of innovative treatment options, including laser therapy, radiofrequency devices, and injectable solutions, is fueling market growth. Moreover, technological advancements in devices and treatments are improving treatment outcomes, offering patients more efficient and lasting results.

• Revelle Aesthetics announced that its Avéli cellulite device has received first international clearance in Australia, following its earlier FDA approval in the United States. This marks a key milestone in expanding the company’s global footprint, with the Avéli device offering a minimally invasive and long-lasting solution for cellulite treatment with minimal downtime.

Key Highlights

1. The cellulite treatment market size was valued at USD 1780.0 million in 2023.
2. The market is projected to grow at a CAGR of 12.54% from 2024 to 2031.
3. North America held a market share of 35.95% in 2023, with a valuation of USD 639.9 million.
4. The non-invasive treatment segment garnered USD 671.7 million in revenue in 2023.
5. The soft segment is expected to reach USD 1743.0 million by 2031.
6. The clinics & beauty centers segment is anticipated to witness the fastest CAGR of 12.66% during the forecast period
7. Asia Pacific is anticipated to grow at a CAGR of 13.45% during the forecast period.

Market Driver

Rising Popularity of Non-Invasive and Minimally Invasive Treatments

The increasing preference for non-invasive and minimally invasive treatments is fueling the growth of the market, as patients seek safer, more effective, and convenient alternatives to traditional surgical procedures. Advanced technologies such as laser therapy, radiofrequency (RF), ultrasound, and injectables deliver effective results with minimal downtime and lower risk. 

Innovations in aesthetic medicine, including combination therapies, have enhanced treatment efficacy and patient satisfaction. The rising demand for personalized treatment approaches tailored to different skin types and cellulite severity further supports this shift. 

In August 2023, the American Society of Plastic Surgeons published an article that stated the growing demand for noninvasive aesthetic procedures is driven by enhanced accessibility, increased consumer awareness, and technological advancements. These innovations offer effective appearance-enhancing solutions with minimal downtime, making them more appealing.

• Similarly, according to the National Library of Medicine, a recent survey reported a 3.4% global rise in aesthetic procedures, with plastic surgeons performing 34.9 million surgical and nonsurgical treatments in 2023. This included over 15.8 million surgical procedures and more than 19.1 million nonsurgical interventions, reflecting sustained global demand for aesthetic enhancements.

Market Challenge

High Treatment Costs

High treatment costs present a significant challenge to the development of cellulite treatment market, limiting access to these treatments for a wide range of consumers. Advanced treatments, such as laser therapy, radiofrequency, and ultrasound-based technologies, often entail substantial costs, including the need for multiple sessions to achieve optimal results. 

Additionally, the requirement for ongoing maintenance sessions to sustain results further increases the financial burden. This cost barrier limits the adoption of these treatments, particularly in developing markets where affordability is a critical factor.

To mitigate this challenge, companies are introducing affordable financing options, such as installment plans or partnerships with insurance providers, which enhance accessibility for a wider consumer base. Alternatively, low-cost solutions, such as topical creams or over-the-counter products, can provide more accessible entry points for cost-conscious consumers. 

Educational initiatives aimed at raising awareness of the long-term value and benefits of cellulite treatments can help position these services as an investment in health and appearance.

Market Trend

Technological Advancements in Aesthetic Treatments

A notable trend in the market is the advancements of technology in aesthetic treatments, enhancing efficacy and patient experience. Innovations such as AI-driven diagnostic tools enable the precise assessment of cellulite severity, allowing for more personalized treatment plans. 

Combination therapies, which integrate multiple modalities such as Radiofrequency  (RF) with injectables  or mechanical massages, are gaining popularity for delivering longer-lasting and more effective results. Furthermore, the emergence of non-invasive and pain-free solutions, such as microneedling and acoustic wave therapy, is expanding treatment accessibility to patients seeking minimal downtime.

• In September 2023, the National Library of Medicine published a study in Skin Health and Disease introducing the Square Technique, a minimally invasive cellulite treatment using large-gel-particle hyaluronic acid (HA). This method combines non-traumatic subcision with HA fillers, offering quick results, minimal risks, and high patient satisfaction.

Cellulite Treatment Market Report Snapshot

Segmentation	Details
By Procedure	Non-invasive treatment, Minimally invasive treatment, Topical treatment
By Cellulite Type	Soft, Hard, Edematous
By End Use	Hospitals, Clinics & Beauty Centers, Others
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation

• By Procedure (Non-invasive treatment, Minimally invasive treatment, and Topical treatment): The non-invasive treatment segment earned USD 671.7 million in 2023 due to rising consumer preference for painless procedures, minimal downtime, and advancements in laser, radiofrequency, and ultrasound technologies.
• By Cellulite Type (Soft, Hard, and Edematous): The soft segment held a share of 38.45% in 2023, propelled by its higher prevalence, easier treatability with non-invasive methods, and growing consumer demand for aesthetic procedures.
• By End Use (Hospitals, Clinics & Beauty Centers, and Others): The hospitals segment is projected to reach USD 1889.0 million by 2031, propelled by increasing demand for advanced medical treatments and the growing preference for clinically supervised procedures. 

Cellulite Treatment Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

The North American cellulite treatment market share stood at around 35.95% in 2023, valued at USD 639.9 million. This dominance is attributed to the region’s high consumer awareness, strong demand for aesthetic procedures, and the presence of advanced healthcare infrastructure. 

The regional market benefits from a large number of dermatology clinics, cosmetic surgery centers, and key market players investing in innovative cellulite treatment technologies. Additionally, favorable reimbursement policies, increasing disposable income, and the influence of social media trends contribute to regional market growth.

The Asia-Pacific cellulite treatment industry is likely to grow at a CAGR of 13.45% over the forecast period. This growth is attributed to rising medical tourism, increasing awareness of aesthetic treatments, and expanding healthcare infrastructure in countries such as China, India, South Korea, and Japan. 

The region is witnessing a surge in disposable income, a growing middle-class population, and a higher demand for non-invasive cosmetic procedures. The presence of local and international aesthetic brands, coupled with technological advancements in skincare and body contouring, is fostering regional market expansion.

• In September 2023, Caliway Biopharmaceuticals announced the completion of subject recruitment for its CBL-0201EFP Phase 2-stage 2 study, evaluating the CBL-514 for treating moderate to severe cellulite. The open-label study enrolled 23 subjects, all of whom will receive CBL-514 treatment.

Regulatory Frameworks

• In the EU, the Medical Device Regulation (MDR) (Regulation (EU) 2017/745) ensures the safety, performance, and compliance of cellulite treatment devices by establishing strict clinical evaluation, post-market surveillance, and risk management requirements before market entry.
• In Australia, the Australian Regulatory Guidelines for Medical Devices (ARGMD) ensure the safety, quality, and performance of cellulite treatment devices by outlining requirements for classification, approval, post-market monitoring, and compliance under the Therapeutic Goods Administration (TGA) framework.
• In Canada, the Medical Devices Regulations (SOR/98-282) ensure the safety, effectiveness, and quality of cellulite treatment devices by establishing requirements for licensing, labeling, post-market surveillance, and risk management under Health Canada’s regulatory framework.

Competitive Landscape

The cellulite treatment market is characterized by intense competition among key players, constant product innovations, and strategic collaborations to expand market presence. Leading companies are focusing on R&D to enhance treatment efficacy, introduce advanced devices, and improve patient outcomes. 

Mergers, acquisitions, and partnerships with dermatology clinics and aesthetic centers are strengthening distribution networks. Moreover, increasing investments in marketing campaigns, influencer endorsements, and direct-to-consumer sales channels are shaping brand positioning.

• In November 2024, Wellness Zone Studio, a premier health and wellness center in Willowbrook, Illinois, expanded its services to include Lipomassage by Endermologie, a non-invasive treatment aimed at reducing cellulite and improving skin tone. This highlights the studio’s commitment to offering cutting-edge therapies that enhance overall well-being and client satisfaction.

List of Key Companies in Cellulite Treatment Market:

• Alma Lasers Ltd
• AbbVie Inc
• Merz Pharma
• REVANCE AESTHETICS.
• Zimmer MedizinSystems Aesthetic Division
• Galderma
• Hologic, Inc.
• Cutera Aesthetics
• Lumenis Be Ltd
• Beijing Nubway S&T Co.,Ltd.
• Inceler Medikal Co. Ltd.
• Candela Corporation
• Bausch Health Companies Inc
• Inmode Ltd
• ENDYMED

Recent Developments (M&A)

• In November 2024, Tiger Aesthetics Medical, LLC acquired Revelle Aesthetics and its Avéli cellulite reduction device, an FDA-cleared, single-use tool offering a minimally invasive solution to treat cellulite. This acquisition expands Tiger Aesthetics' portfolio in regenerative body aesthetics, addressing the growing demand for lower body rejuvenation.